Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173948
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pastick, Katelyn A. | - |
dc.contributor.author | Okafor, Elizabeth C. | - |
dc.contributor.author | Wang, Fan | - |
dc.contributor.author | Lofgren, Sarah M. | - |
dc.contributor.author | Skipper, Caleb P. | - |
dc.contributor.author | Nicol, Melanie R. | - |
dc.contributor.author | Pullen, Matthew F. | - |
dc.contributor.author | Rajasingham, Radha | - |
dc.contributor.author | McDonald, Emily G | - |
dc.contributor.author | Lee, Todd C. | - |
dc.contributor.author | Schwartz, Ilan S. | - |
dc.contributor.author | Kelly, Lauren E. | - |
dc.contributor.author | Lother, Sylvain A. | - |
dc.contributor.author | Mitjà Villar, Oriol | - |
dc.contributor.author | Letang, Emilio | - |
dc.contributor.author | Abassi, Mahsa | - |
dc.contributor.author | Boulware, David R. | - |
dc.date.accessioned | 2021-02-15T11:29:38Z | - |
dc.date.available | 2021-02-15T11:29:38Z | - |
dc.date.issued | 2020-04-15 | - |
dc.identifier.issn | 2328-8957 | - |
dc.identifier.uri | http://hdl.handle.net/2445/173948 | - |
dc.description.abstract | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Oxford University Press; Infectious Diseases Society of America | - |
dc.relation.isformatof | Reproducció del document publicat a: http://dx.doi.org/10.1093/ofid/ofaa130 | - |
dc.relation.ispartof | Open Forum Infectious Diseases, 2020, vol. 7, num. 4 | - |
dc.relation.uri | http://dx.doi.org/10.1093/ofid/ofaa130 | - |
dc.rights | cc by-nc-nd (c) Pastick et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | - |
dc.source | Articles publicats en revistes (ISGlobal) | - |
dc.subject.classification | SARS-CoV-2 | - |
dc.subject.classification | Parasitologia mèdica | - |
dc.subject.other | SARS-CoV-2 | - |
dc.subject.other | Medical parasitology | - |
dc.title | Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-02-12T19:01:21Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 32363212 | - |
Appears in Collections: | Articles publicats en revistes (ISGlobal) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Pastik_KA_Open_Forum_Infect_Dis_2020.pdf | 207.42 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License